OTCM
LZAGF
Market cap52bUSD
, Last price
Name
Lonza Group AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
Related entities
Subsidiaries (14)
CAPSUGEL BELGIUM
CAPSUGEL FRANCE
LONZA FINANCE INTERNATIONAL NV
LONZA INDIA PRIVATE LIMITED
LONZA SALES AG
LONZA SWISS FINANZ AG
LONZA VERVIERS
CAPSUGEL HUNGARY KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG
CAPSUGEL ITALY SOCIETÀ A RESPONSABILITÀ LIMITATA
CAPSUGEL SPAIN SL
INNOVATIVE WATER CARE EUROPE SAS
INNOVATIVE WATER CARE LIMITED
LONZA BIOLOGICS PLC
MW ENCAP LIMITED
Key people
Jean Marc Huet
Independent Chairman of the Board · since 2024
Philippe Deecke
Chief Financial Officer, Member of the Executive Committee · since 2021
Gordon Bates
Head of Integrated Biologics, Member of the Executive Committee · since 2025
Nicoleta Baumgartner
Chief Human Resources Officer, Member of the Executive Committee · since 2024
Jason Berndt
Head of Group Operations and Member of the Executive Committee · since 2025
Andreas Bohrer
Chief Legal & Corporate Affairs Officer and Member of the Executive Committee · since 2025
Jean-Christophe Hyvert
Head of Capsules & Health Ingredients, Member of the Executive Committee · since 2025
Maria Nunez
Chief Quality Officer, Member of the Executive Committee · since 2025
Daniel Palmacci
Head of Specialized Modalities, Member of the Executive Committee · since 2025
Christian Seufert
Head of Advanced Synthesis, Member of the Executive Committee · since 2025
Chief Executive Officer, Member of the Executive Committee · since 2024
Lead Independent Director · since 2024
Independent Member of the Board · since 2025
Marion Helmes
Independent Member of the Board · since 2022
Angelica Kohlmann
Independent Member of the Board · since 2018
Independent Member of the Board · since 2025
Roger Nitsch
Independent Member of the Board · since 2022
Independent Member of the Board · since 2014
Independent Non-Executive Vice Chairman of the Board · since 2024
Legal address
MUNCHENSTEINERSTR. 38
BASEL, BS 4052
CH
BASEL, BS 4052
CH
Headquarters
MÜNCHENSTEINERSTR. 38
BASEL, BS 4052
CH
BASEL, BS 4052
CH
Previous name
AXERA AG
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||